June 30, 2020 / 12:15 PM / 7 days ago

BRIEF-Rubius Therapeutics Provides Update On Clinical Trial Progress For Lead Oncology Product Candidate

June 30 (Reuters) - Rubius Therapeutics Inc:

* RUBIUS THERAPEUTICS PROVIDES UPDATE ON CLINICAL TRIAL PROGRESS FOR ITS LEAD ONCOLOGY PRODUCT CANDIDATE RTX-240 AND ANNOUNCES PLANNED LEADERSHIP TRANSITION

* RUBIUS THERAPEUTICS - COMPLETED DOSING OF FIRST DOSE-ESCALATION COHORT WITH NO OBSERVED ADVERSE EVENTS TO DATE IN PHASE 1/2 CLINICAL TRIAL OF RTX-240

* RUBIUS THERAPEUTICS - ANDREW OH, CFO WILL DEPART CO FOLLOWING COMPLETION OF A TRANSITION PERIOD

* RUBIUS THERAPEUTICS - CO HAS INITIATED A SEARCH FOR ITS NEXT CFO Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below